Drug intelligence / Profile preview

SCTV01

Development stage: Unknown
Lead developer: Sinocelltech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

SCTV01 is a multivalent therapeutic cancer vaccine developed by Sinocelltech. It is designed to stimulate the immune system to recognize and attack tumor cells by targeting multiple tumor-associated antigens simultaneously. This multivalent approach is intended to address tumor heterogeneity and prevent immune escape, which are common challenges in oncology. SCTV01 is currently being evaluated in Phase 1/2 clinical trials for the treatment of various solid tumors and cancers, aiming to induce a broad and robust anti-tumor immune response.

Other names: multivalent tumor vaccine多价肿瘤疫苗

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on SCTV01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCTV01.

Explore the full profile